Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Hester Biosciences Ltd Interim / Quarterly Report 2021

Jan 30, 2021

62222_rns_2021-01-30_6586365a-dcda-429b-8265-c5067265edec.pdf

Interim / Quarterly Report

Open in viewer

Opens in your device viewer

Page 1 of 5

==> picture [521 x 96] intentionally omitted <==

Press Release

30 January 2021

Q3FY21 Sales up by 22%, 9MFY21 Sales up by 14%

Q3FY21 Net Profit up by 72%, 9MFY21 Net Profit up by 18%

Financial Highlights

Financial Highlights Financial Highlights Financial Highlights
INR in Million
Particulars **Q3 ** 9M
FY21 FY20 Growth FY21 FY20 Growth
Net Sales 528.18 433.93 22% 1,453.19 1,279.94 14%
Net Profit 132.91 77.30 72% 310.42 262.21 18%
EPS(In INR) 15.62 9.09 72% 36.49 30.82 18%

Division-wise sales in INR Million

Particulars **Q3 ** **Q3 ** **Q3 ** 9M 9M 9M
FY21 FY20 Growth FY21 FY20 Growth
Poultry Healthcare 396.09 300.24 32% 1,037.77 904.61 15%
Animal Healthcare 98.97 94.82 4% 308.27 258.83 19%
Other 33.12 38.87 (15%) 107.15 116.50 (8%)
TOTAL 528.18 433.93 22% 1,453.19 1,279.94 14%

Profitability Analysis

Particular Q3FY21 Q3FY20 9MFY21 9MFY20 FY20
GP Margin 68.22% 66.76% 64.04% 67.37% 66.97%
EBIDTA Margin 38.97% 29.97% 35.35% 33.17% 31.12%
NP Margin 25.16% 17.81% 21.36% 20.49% 18.43%
EPS in INRNon-Annualised 15.62 9.09 36.49 30.82 36.70

Balance Sheet Analysis

**Particular ** Q3FY21 Q3FY20 Up/(Down) 9MFY21 9MFY20 Up/(Down)
ROE 23.24% 15.60% 7.64% 18.05% 17.60% 0.45%
ROCE 26.66% 17.82% 8.84% 22.65% 19.84% 2.81%
ROI 18.55% 11.11% 7.44% 14.41% 12.53% 1.88%

Page 2 of 5

==> picture [521 x 96] intentionally omitted <==

Business Overview of Hester India
Analysing the performance through various parameters:
Business Overview of Hester India
Analysing the performance through various parameters:
1. Poultry Healthcare
Division
It has registered a growth of 32% in Q3FY21 and 15% in 9MFY21 in
comparison to the corresponding period last year.
2. Animal Healthcare
Division
It has registered growth of 4% in Q3FY21 and 19% in 9MFY21. The
seemingly low growth of 4% on a Q-to-Q basis is purely due to large
tender orders received last year in Q3 as against not received this year
in Q3.
3. Vaccine sales (poultry and animal divisions) have registered growth of 20% in Q3FY21
and 12% in 9MFY21 as compared to the corresponding period last year.
4. Health product sales (poultry and animal divisions) have registered growth of 48% in Q3FY21
and 31% in 9MFY21 as compared to the corresponding period last year.
5. Geography Domestic sales have registered a growth of 43% in Q3FY21 and 20% in
9MFY21 and the export sales have reduced by 51% in Q3FY21 and 5%
in 9MFY21. While export orders have continued to pour in, the higher
demand within India compelled us to divert the production for domestic
sales.
6. Brucella tender The outcome of the tender for Brucella vaccine under the National Animal
Disease Control Program of the Government of India is awaited. Sales
through this tender are expected to commence from March 2021.
7. Bird Flu impact There has been no impact on our sales due to the current Bird Flu
situation in India.

Going further:

  1. Hester is set to launch a new range of Herbal Health products in this quarter.

  2. Vaccine production expansion plans have been finalised for India. We hope to embark on the expansion activities in this quarter, the details would be shared in the next few weeks.

  3. In view of the various vaccine opportunities within India, including those of Brucella and LSD vaccines, till our expansion activities go on-stream, temporarily, Hester will focus on the Indian market. Exports will be mainly of health products.

  4. Hester is also evaluating expansion opportunities in manufacturing and distribution of Animal Health Products and Biologicals, worldwide.

  5. The Board has authorised the management to explore appropriate financing alternatives for the expansion activities for an aggregate outlay of INR 2 billion.

  6. Our developmental activities are ongoing for the human Covid-19 vaccine with IIT Guwahati.

Business Overview of Hester Nepal

  1. Revenue for Q3FY21 was recorded at INR 36.20 Mn as against INR 8.69 Mn in Q3FY20.

  2. Revenue for 9MFY21 was recorded at INR 43.33 Mn as against INR 45.36 Mn in 9MFY20.

Q3FY21 has performed as per expectations. FAO Tenders for PPR have now started, (though in a small way), which has resulted in increase in top-line in Q3FY21 and we are expecting the same to follow in the coming part of the year.

Financials in INR Million

Particular Q3FY21 Q3FY20 9MFY21 9MFY20 FY20
Net Sales 36.20 8.69 43.33 45.36 161.80
Net Profit/ (Loss) 9.41 6.54 (16.54) (18.36) 39.39

Page 3 of 5

==> picture [521 x 96] intentionally omitted <==

Business Overview of Texas Lifesciences

  1. Revenue for Q3FY21 was recorded at INR 51.69 Mn as against INR 33.31 Mn in Q3FY20.

  2. Revenue for 9MFY21 was recorded at INR 113.07 Mn as against INR 93.09 Mn in 9MFY20.

Texas Lifesciences has continued to show growth in topline due to the growth in sales of health products at Hester.

The company has also started direct registration process for products to be exported to various African countries.

Financials in INR Million

Particular Q3FY21 Q3FY20 9MFY21 9MFY20 FY20
Net Sales 51.69 33.31 113.07 93.09 128.03
Net Profit/ (Loss) 4.44 4.70 9.70 9.99 10.17

Business Overview of Hester Tanzania

  1. Revenue for Q3FY21 was recorded at INR 16.61 Mn as against INR 8.87 Mn in Q3FY20.

  2. Revenue for 9MFY21 was recorded at INR 32.18 Mn as against INR 20.86 Mn in 9MFY20.

Company is in process of establishing sales and distribution network keeping in focus the Demands from domestic market as well as East African countries

Financials in INR Million

Particular Q3FY21 Q3FY20 9MFY21 9MFY20 FY20
Net Sales 16.61 8.87 32.18 20.86 27.03
Net Profit/ (Loss) 8.86 8.22 0.47 13.35 (2.68)

Business Overview of Hester Africa

The project is near completion. Commercial production has been slated for June 2021.

==> picture [53 x 55] intentionally omitted <==

Rajiv Gandhi Hester Biosciences Limited CEO Managing Director

Page 4 of 5

Hester India:

==> picture [451 x 254] intentionally omitted <==

Hester Nepal:

==> picture [451 x 302] intentionally omitted <==

Page 5 of 5

==> picture [72 x 9] intentionally omitted <==

----- Start of picture text -----

Hester Africa:
----- End of picture text -----

==> picture [451 x 254] intentionally omitted <==

==> picture [91 x 88] intentionally omitted <==

Better health for human beings through healthier animals